Drugs / SPYVLP01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06145178 | Nov 2023 → Jun 2025 | cytomegalovirus infection | SpyBiotech Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-09-20 | SpyBiotech Limited | Regulatory SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01 spybiotech.com ↗
SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced that the company has filed a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate SPYVLP01, a vaccine targeting human cytomegalovirus (HCMV) using its Hepatitis B virus-like-particle platform technology. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-07-23 | SpyBiotech Limited | SpyBiotech Announces the Completion of Enrollment in Phase I Trial of SPYVLP01 Targeting Human Cytomegalovirus (HCMV) spybiotech.com ↗ |
| 2023-12-07 | SpyBiotech Limited | SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01 spybiotech.com ↗ |
| 2023-09-20 | SpyBiotech Limited | SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01 spybiotech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPYVLP01 | “Novel vaccine SPYVLP01” NCT06145178 ↗ |
| Modality | Vaccine | “Novel vaccine SPYVLP01” NCT06145178 ↗ |